Fractyl Health Files 8-K: Regulation FD & Exhibits
Ticker: GUTS · Form: 8-K · Filed: Jun 24, 2024 · CIK: 1572616
| Field | Detail |
|---|---|
| Company | Fractyl Health, Inc. (GUTS) |
| Form Type | 8-K |
| Filed Date | Jun 24, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, exhibits, filing
TL;DR
Fractyl Health filed an 8-K on 6/24/24 for Reg FD and exhibits. No major news yet.
AI Summary
On June 24, 2024, Fractyl Health, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates routine corporate disclosures and the submission of financial statements, which are standard for public companies and provide transparency to investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any immediate material adverse events.
Key Numbers
- 001-41942 — SEC File Number (Identifies the company's filing history with the SEC.)
- 27-3553477 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Fractyl Health, Inc. (company) — Registrant
- June 24, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 3 Van de Graaff Drive Suite 200 (address) — Principal Executive Offices
- Burlington, Massachusetts (location) — Principal Executive Offices City and State
- 01803 (zip_code) — Principal Executive Offices Zip Code
FAQ
What specific information is being disclosed under Regulation FD?
The provided excerpt does not detail the specific information disclosed under Regulation FD, only that it is an item of disclosure.
What financial statements and exhibits are included in this filing?
The excerpt states that 'Financial Statements and Exhibits' are part of the filing, but does not list the specific documents.
When was Fractyl Health, Inc. incorporated?
Fractyl Health, Inc. was incorporated in Delaware, as stated in the filing.
What is the principal executive office address for Fractyl Health, Inc.?
The principal executive offices are located at 3 Van de Graaff Drive, Suite 200, Burlington, Massachusetts, 01803.
Has the company's name changed previously?
Yes, the company was formerly known as Fractyl Health, Inc. (name change effective 20210617) and prior to that, Fractyl Laboratories Inc. (name change effective 20130320).
Filing Stats: 576 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-06-24 06:04:14
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value per share GUTS The Nasdaq
Filing Documents
- guts-20240624.htm (8-K) — 42KB
- guts-ex99_1.htm (EX-99.1) — 33KB
- 0000950170-24-076424.txt ( ) — 198KB
- guts-20240624.xsd (EX-101.SCH) — 25KB
- guts-20240624_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On June 24, 2024, Fractyl Health, Inc. (the "Company") issued a press release announcing that the Company provided corporate updates, including regarding the Revita weight maintenance clinical study REMAIN-1 and REVEAL-1 cohort, and the Revita type 2 diabetes clinical study REVITALIZE-1. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company has posted an updated corporate slide presentation to reflect recent business updates. The updated slide presentation can be found on the Company's investor relations website https://ir.fractyl.com. The information contained in Item 7.01 of this Current Report (including Exhibit 99.1 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibit relates to Item 7.01 and shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Fractyl Health, Inc. Press Release dated June 24, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Fractyl Health, Inc. Date: June 24, 2024 By: /s/ Harith Rajagopalan Harith Rajagopalan, M.D., Ph.D. Chief Executive Officer